Autoimmune and autoinflammatory arthritis: HMGB1 as a biomarker and therapeutic target

On May 20th, World AUTOimmune & AUTOinflammatory Arthritis Day, highlights the global impact of autoimmune and autoinflammatory arthritis, affecting an estimated 450 million people worldwide. This anniversary emphasizes the necessity of advancing our understanding and treatment strategies for these debilitating conditions.

A recent research has shown the impacting role of High Mobility Group Box 1 (HMGB1) in autoimmune diseases. HMGB1, nucleoprotein expressed in almost all eukaryotic cells, serves as a vital biomarker and potential therapeutic target in this context. Its interaction with Toll-like receptors (TLRs), especially TLR2 and TLR4, transforms it into a pro-inflammatory cytokine that contributes to the pathogenesis of various autoimmune conditions, including rheumatoid arthritis, systemic lupus erythematosus and thyroid diseases.
As HMGB1 and TLRs are upregulated in several autoimmune diseases, they represent significant targets for therapeutic intervention. Suppressing these molecules has shown promises in reducing inflammation and potentially altering the disease course in various models.

World AUTOimmune & AUTOinflammatory Arthritis Day reminds us the commitment to transform the lives of those affected by such diseases, through advanced research and targeted therapies: HMGBiotech is at the forefront of research on HMGB1, providing innovative solutions and comprehensive resources for researchers studying its role in autoimmune diseases.

In HMGBiotech we can provide comprehensive information to facilitate informed decision-making for research involving HMGB1.
Contact us for your pre-sales questions about HMGB1

Read the full article about the study:

Shopping Cart